Management of patients with pulmonary arterial hypertension due to congenital heart disease: recent advances and future directions

References

• Baumgartner H, Bonhoeffer P, De Groot NMS, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–2957.
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation . Eur Heart J. 2009;30:2493–2537.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.
   PubMed Web of Science ®Google Scholar
• Van Der Bom T, Bouma BJ, Meijboom FJ, et al. The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. Am Heart J. 2012;164:568–575.
   PubMed Web of Science ®Google Scholar
• Vis JC, Van Der Velde ET, Schuuring MJ, et al. WANTED! 8000 heart patients: identification of adult patients with a congenital heart defect lost to follow-up. Int J Cardiol. 2011;149:246–247.
   PubMed Web of Science ®Google Scholar
• Van Riel ACMJ, Schuuring MJ, Van Hessen ID, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014;174:299–305.
   PubMed Web of Science ®Google Scholar
• Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011;58:538–546.
   PubMed Web of Science ®Google Scholar
• Strange G, Rose M, Kermeen F, et al. A binational registry of adults with pulmonary arterial hypertension complicating congenital heart disease. Intern Med J. 2015;45:944–950.
   PubMed Web of Science ®Google Scholar
• Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, et al. Pulmonary hypertension and congenital heart disease: an insight from the REHAP national registry. Int J Cardiol. 2015;184:717–723.
   PubMed Web of Science ®Google Scholar
• Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35:716–724.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lopez J. Pulmonary hypertension in adult congenital heart disease. Curr Treat Options Cardiovasc Med. 2014;16:328.
   PubMedGoogle Scholar
• Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol. 2008;129:163–171.
   PubMed Web of Science ®Google Scholar
• Schwerzmann M, Zafar M, McLaughlin PR, et al. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy. Int J Cardiol. 2006;110:104–107.
   PubMed Web of Science ®Google Scholar
• Frost AE, Quiñones MA, Zoghbi WA, et al. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant. 2005;24:501–503.
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Yu JJ, Yun T-J, et al. Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy. Ann Thorac Surg. 2010;89:1629–1630.
   PubMed Web of Science ®Google Scholar
• Rao PSM, Raju V, Narayana M. Flap valved closure of ventricular septal defects with increased pulmonary vascular resistance. Interact Cardiovasc Thorac Surg. 2010;11:577–580.
   PubMedGoogle Scholar
• Dell’avvocata F, Rigatelli G, Cardaioli P, et al. Home-made fenestrated amplatzer occluder for atrial septal defect and pulmonary arterial hypertension. J Geriatr Cardiol. 2011;8:127–129.
   PubMed Web of Science ®Google Scholar
• Kretschmar O, Sglimbea A, Corti R, et al. Shunt reduction with a fenestrated Amplatzer device. Catheter Cardiovasc Interv. 2010;76:564–571.
   PubMed Web of Science ®Google Scholar
• Kamali H, Saritas T, Erdem A, et al. Percutaneous closure of large VSD using a home-made fenestrated atrial septal occluder in 18-year-old with pulmonary hypertension. BMC Cardiovasc Disord. 2014;14:74.
   PubMed Web of Science ®Google Scholar
• Keogh AM, Nicholls M, Shaw M, et al. Modified Potts shunt in an adult with pulmonary arterial hypertension and recurrent syncope - three-year follow-up. Int J Cardiol. 2015;182:36–37.
   PubMed Web of Science ®Google Scholar
• Bentham JR, Thomson JDR. Current state of interventional cardiology in congenital heart disease. Arch Dis Child. 2015;100:787–792.
   PubMed Web of Science ®Google Scholar
• Mackie AS, Ionescu-Ittu R, Therrien J, et al. Children and adults with congenital heart disease lost to follow-up: who and when? Circulation. 2009;120:302–309.
   PubMed Web of Science ®Google Scholar
• Gabriels C, De Meester P, Pasquet A, et al. A different view on predictors of pulmonary hypertension in secundum atrial septal defect. Int J Cardiol. 2014;176:833–840.
   PubMed Web of Science ®Google Scholar
• Van Riel ACMJ, Blok IM, Zwinderman AH, et al. Life time risk of pulmonary hypertension for all patients after shunt closure. J Am Coll Cardiol. 2015;66:1084–1086.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College. Circulation. 2009;119:2250–2294.
   PubMed Web of Science ®Google Scholar
• Winter MM, Mulder BJM, van der Velde ET. Letter by Winter et al regarding article, “Children and adults with congenital heart disease lost to follow-up: who and when?”. Circulation. 2010;121:e252. author reply e253.
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60–72.
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–1865.
   PubMed Web of Science ®Google Scholar
• Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91:632–635.
   PubMed Web of Science ®Google Scholar
• Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol. 2013;168:4117–4121.
   PubMed Web of Science ®Google Scholar
• Cha KS, Cho KI, Seo JS, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER study). Am J Cardiol. 2013;112:1834–1839.
   PubMed Web of Science ®Google Scholar
• Caojin Z, Yigao H, Tao H, et al. Comparison of acute hemodynamic effects of aerosolized iloprost and inhaled nitric oxide in adult congenital heart disease with severe pulmonary arterial hypertension. Intern Med. 2012;51:2857–2862.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–1619.
   PubMed Web of Science ®Google Scholar
• Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54.
   PubMed Web of Science ®Google Scholar
• Guo L, Liu Y-J, Xie Z-L. Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2014;18:638–645.
   PubMed Web of Science ®Google Scholar
• Diller G-P, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. 2013;167:840–847.
   PubMed Web of Science ®Google Scholar
• Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164:64–69.
   PubMed Web of Science ®Google Scholar
• Crepaz R, Romeo C, Montanaro D, et al. Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart disease. BMC Cardiovasc Disord. 2013;13:74.
   PubMed Web of Science ®Google Scholar
• Serino G, Guazzi M, Micheletti A, et al. Effect of bosentan on exercise capacity and clinical worsening in patients with dual Down and Eisenmenger syndrome. Clin Med Insights Cardiol. 2013;7:29–34.
   PubMedGoogle Scholar
• Baptista R, Castro G, da Silva AM, et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013;32:123–129.
   PubMedGoogle Scholar
• Duffels MGJ, Vis JC, van Loon RLE, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134:378–383.
   PubMed Web of Science ®Google Scholar
• Monfredi O, Griffiths L, Clarke B, et al. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am J Cardiol. 2011;108:1483–1488.
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–3019.
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971–1981.
   PubMed Web of Science ®Google Scholar
• Condliffe R, Elliot CA, Hurdman J, et al. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis. 2014;8:71–77.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818.
   PubMed Web of Science ®Google Scholar
• Channick RN, Delcroix M, Ghofrani H-A, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3:1–8.
   PubMed Web of Science ®Google Scholar
• Duffels MGJ, Vis JC, van Loon RLE, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am J Cardiol. 2009;103:1309–1315.
   PubMed Web of Science ®Google Scholar
• Schuuring MJ, Boekholdt SM, Windhausen A, et al. Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. Neth Heart J. 2011;19:509–513.
   PubMed Web of Science ®Google Scholar
• Schuuring MJ, van Riel ACMJ, Vis JC, et al. New predictors of mortality in adults with congenital heart disease and pulmonary hypertension: midterm outcome of a prospective study. Int J Cardiol. 2014;181C:270–276.
   Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157.
   PubMed Web of Science ®Google Scholar
• Lu X-L, Xiong C-M, Shan G-L, et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther. 2010;28:350–355.
   PubMed Web of Science ®Google Scholar
• Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1–5.
   Web of Science ®Google Scholar
• Zeng W-J, Lu X-L, Xiong C-M, et al. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol. 2011;34:513–518.
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006;114:1807–1810.
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–340.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45:1303–1313.
   PubMed Web of Science ®Google Scholar
• Kemp K, Savale L, O’Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2012;31:150–158.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43:1691–1697.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353–359.
   PubMed Web of Science ®Google Scholar
• Bai Y, Sun L, Hu S, et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011;120:157–165.
   PubMed Web of Science ®Google Scholar
• Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011;108:1177–1182.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–1263.
   PubMed Web of Science ®Google Scholar
• Gruenig E, Michelakis E, Vachiéry J-L, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol. 2009;49:1343–1352.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing Z-C, Xu K-F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144:952–958.
   PubMed Web of Science ®Google Scholar
• Galiè N, Müller K, Scalise A-V, et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45:1314–1322.
   PubMed Web of Science ®Google Scholar
• Sharif Kashani B, Tahmaseb Pour P, Malekmohammad M, et al. Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger syndrome: a clinical trial. J Cardiol. 2014;64:231–235.
   PubMed Web of Science ®Google Scholar
• Gurtu V, Michelakis ED. Emerging therapies and future directions in pulmonary arterial hypertension. Can J Cardiol. 2015;31:489–501.
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830–840.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147–3197.
   PubMed Web of Science ®Google Scholar
• Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2009;30:256–265.
   PubMed Web of Science ®Google Scholar
• Weiss BM, Zemp L, Seifert B, et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31:1650–1657.
   PubMed Web of Science ®Google Scholar
• Greutmann M, Pieper PG. Pregnancy in women with congenital heart disease. Eur Heart J. 2015;36:2491–2499.
   PubMed Web of Science ®Google Scholar
• Graham TP, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol. 2005;45:1326–1333.
   PubMed Web of Science ®Google Scholar
• Dua JS, Cooper AR, Fox KR, et al. Exercise training in adults with congenital heart disease: feasibility and benefits. Int J Cardiol. 2010;138:196–205.
   PubMed Web of Science ®Google Scholar
• Martínez-Quintana E, Miranda-Calderín G, Ugarte-Lopetegui A, et al. Rehabilitation program in adult congenital heart disease patients with pulmonary hypertension. Congenit Heart Dis. 2010;5:44–50.
   PubMed Web of Science ®Google Scholar
• Van der Bom T, Winter MM, Knaake JL, et al. Long-term benefits of exercise training in patients with a systemic right ventricle. Int J Cardiol. 2014;179C:105–111.
   Google Scholar
• Harinck E, Hutter PA, Hoorntje TM, et al. Air travel and adults with cyanotic congenital heart disease. Circulation. 1996;93:272–276.
   PubMed Web of Science ®Google Scholar
• Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart. 2007;93:1599–1603.
   PubMed Web of Science ®Google Scholar
• Moons P, Canobbio MM, Budts W. Eisenmenger syndrome: a clinical review. Eur J Cardiovasc Nurs. 2009;8:237–245.
   PubMed Web of Science ®Google Scholar
• Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med. 1998;128:745–755.
   PubMed Web of Science ®Google Scholar
• Somerville J. How to manage the Eisenmenger syndrome. Int J Cardiol. 1998;63:1–8.
   PubMed Web of Science ®Google Scholar
• Korsholm K, Andersen A, Kirkfeldt RE, et al. Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. Pulm Circ. 2015;5:364–369.
   PubMed Web of Science ®Google Scholar
• Diller G-P, Alonso-Gonzalez R, Kempny A, et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart. 2012;98:736–742.
   PubMed Web of Science ®Google Scholar
• Moceri P, Dimopoulos K, Liodakis E, et al. Echocardiographic predictors of outcome in Eisenmenger syndrome. Circulation. 2012;126:1461–1468.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL registry). Am J Cardiol. 2014;113:147–155.
   PubMed Web of Science ®Google Scholar
• Scognamiglio G, Kempny A, Price LC, et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart. 2014;100:1335–1341.
   PubMed Web of Science ®Google Scholar
• Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol. 1999;84:677–681.
   PubMed Web of Science ®Google Scholar
• Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106:319–324.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122:164–172.
   PubMed Web of Science ®Google Scholar
• Jansa P, Jarkovsky J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2015;14:1–9.
   Google Scholar
• Van De Bruaene A, De Meester P, Voigt J-U, et al. Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome. Int J Cardiol. 2013;168:1386–1392.
   PubMed Web of Science ®Google Scholar
• Ramos RP, Arakaki JSO, Barbosa P, et al. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. Am Heart J. 2012;163:580–588.
   PubMed Web of Science ®Google Scholar
• Giannakoulas G, Mouratoglou S-A, Gatzoulis MA, et al. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review. Int J Cardiol. 2014;174:618–623.
   PubMed Web of Science ®Google Scholar
• Blok IM, van Riel ACMJ, Schuuring MJ, et al. Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease. Netherlands Hear J. 2015;23:278–284.
   PubMed Web of Science ®Google Scholar
• Kempny A, Dimopoulos K, Alonso-Gonzalez R, et al. Six-minute walk test distance and resting oxygen saturations but not functional class predict outcome in adult patients with Eisenmenger syndrome. Int J Cardiol. 2013;168:4784–4789.
   PubMed Web of Science ®Google Scholar
• Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60:1192–1201.
   PubMed Web of Science ®Google Scholar
• Van der Bom T, Zomer AC, Zwinderman AH, et al. The changing epidemiology of congenital heart disease. Nat Rev Cardiol. 2011;8:50–60.
   PubMed Web of Science ®Google Scholar
• Baumgartner H. Geriatric congenital heart disease: a new challenge in the care of adults with congenital heart disease? Eur Heart J. 2014;35:683–685.
   PubMed Web of Science ®Google Scholar